Seeking Alpha : Here Is What Analysts Are Saying About SRPT. Posted.
Sarepta Therapeutics Setting Up For Another Move Upward
January 31, 2013 By: RS Analytics
5) Bullish Analyst Sentiment & Price Targets - Analysts covering Sarepta are bullish on the companies prospects - some example from StreetInsider:
Wedbush - Outperform/$70
Burrill - Outperform/$54 price target
Cowen - Outperform initiated on 1/25/2013
Dawson James - Outperform
ThinkEquity - Buy
Lazard Capital - Lazard Capital analyst William Turner said Eteplirsen maximum U.S. rev. opportunity is $750 million and applying 3x-5x market cap/revenue multiple leads to fair value of $83-$139/share.